Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D I Jodrell

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 17, 1998
The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interactionL S Murray, D I Jodrell, J G Morrison, et al.
British Journal of Cancer|June 27, 2002
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancerR E Aird, J Cummings, A A Ritchie, et al.
British Journal of Cancer|May 1, 1991
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancerD I Jodrell, I E Smith, J L Mansi, et al.
Biochemical Pharmacology|October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)A L Jackman, D R Newell, W Gibson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancerD C Smith, D I Jodrell, M J Egorin, et al.
Biochemical Pharmacology|December 20, 2005
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compoundsS M Guichard, R Else, E Reid, et al.
British Journal of Cancer|December 19, 2001
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinomaN A Wong, L Brett, M Stewart, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2005
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175R L Hayward, Q C Schornagel, R Tente, et al.
British Journal of Cancer|October 6, 2012
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cellsY Lin, F M Richards, B-F Krippendorff, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 17, 1998
The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interactionL S Murray, D I Jodrell, J G Morrison, et al.
British Journal of Cancer|June 27, 2002
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancerR E Aird, J Cummings, A A Ritchie, et al.
British Journal of Cancer|May 1, 1991
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancerD I Jodrell, I E Smith, J L Mansi, et al.
Biochemical Pharmacology|October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)A L Jackman, D R Newell, W Gibson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancerD C Smith, D I Jodrell, M J Egorin, et al.
Biochemical Pharmacology|December 20, 2005
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compoundsS M Guichard, R Else, E Reid, et al.
British Journal of Cancer|December 19, 2001
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinomaN A Wong, L Brett, M Stewart, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2005
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175R L Hayward, Q C Schornagel, R Tente, et al.
British Journal of Cancer|October 6, 2012
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cellsY Lin, F M Richards, B-F Krippendorff, et al.
Pageof 6